January 20th 2025
The two companies will be exhibiting together after Gerresheimer’s December 2024 acquisition of Bormioli.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Pharma going for a greener New Year
January 1st 2008While it's unlikely that Al Gore's Nobel Peace Prize will gain him the US Presidency, the award has put global warming firmly in the spotlight (as if it wasn't there already). Reducing its carbon footprint is among the many goals Big Pharma has for the coming year - and beyond. Many energy consumption issues are common to all industries and individuals, such as putting curbs on business travel, bringing renewable energy sources on board and switching off lights in unoccupied rooms, but there are other issues that are specific to our industry. For example, asthma inhalers emit greenhouse gases and many pharmaceutical syntheses use toxic solvents.
20th Anniversary Special Feature: The transformation and future trends of laboratory data management
January 1st 2008Historically, the main purpose of laboratory information management systems (LIMS) has been to track and manage samples in the laboratory. LIMS originated nearly 30 years ago as a rudimentary method of automating manual, error-prone processes in the laboratory and, with the growth in adoption of technology, became the de facto benchmark for laboratory control and management.
Perfect pumps for bio-processing and high-flow sanitary duties
December 10th 2007Perfect pumps for bio-processing and high-flow sanitary duties Watson-Marlow Bredel's 720 series peristaltic pumps are the perfect pumping solution for single-use or fixed bioprocessing systems. Featuring a smaller footprint than other pumps with a similar flow rate, 720 pumps provide low shear pumping up to 4,000 litre/hour and use sanitary LoadSure pumping elements for one minute maintenance.
A FDA Perspective on Quality by Design
December 5th 2007Chi-wan Chen, deputy director of the Office of New Drug Quality Assessment (ONDQA) at the US Food and Drug Administration's Center for Drug Evaluation and Research, shares insight from FDA's pilot program that was designed to allow pharmaceutical companies to submit CMC information demonstrating application of quality by design.
Preparation and Characterization of Meloxicam–Myrj-52 Granules Obtained by Melt Granulation
December 2nd 2007Various manufacturing techniques can improve a drug's solubility, thus increasing its bioavailability. The authors examined whether melt granulation can enhance drug solubility using meloxicam as the drug substance and myrj-52 as the binder.